An oral GLP-1 pill enters Phase 3, and the obesity race gets a new lane
Dr. Dereck Mush, MD, MBA
Yazen
Digital obesity clinic combining modern weight loss medication with continuous multidisciplinary care across Europe.
What they do
Yazen treats obesity as a chronic disease through doctors, dietitians, psychologists and physiotherapists working digitally alongside medication. It operates in eight European countries with over 50,000 patients in active treatment. In October 2026 it secured €50M in a round led by Verdane with Evli Growth Partners.
The record
- Vertical
- Digital Health
- Sub-segment
- Medical obesity care
- Product type
- Care delivery
- Stage
- Growth
- Headquarters
- Stockholm, Sweden
- Region
- Europe
- Founded
- Not disclosed
- Total funding
- $54M raised
Notable investors: Verdane, Evli Growth Partners.
Related on The Signal
Dr. Dereck Mush, MD, MBAThe HealthTech Signal
GLP-1 drugs are excellent at losing weight. The muscle question is where healthspan gets decided
GLP-1 drugs are excellent at losing weight. The muscle question is where healthspan gets decided
Dr. Dereck Mush, MD, MBA
Beyond GLP-1: amylin and triple agonist drugs crowd the next phase of obesity R&D
Dr. Dereck Mush, MD, MBAThe HealthTech Signal
She Lost 60 Pounds on Ozempic. Then Her Insurance Stopped Covering It.
She Lost 60 Pounds on Ozempic. Then Her Insurance Stopped Covering It.
Dr. Dereck Mush, MD, MBA